Penta Hospitals Przychodnie
- Address
- ul. Wejherowska 28, bud. 4, 54-239 Wroclaw, Poland
Digestive System Diseases
At Penta Hospitals Przychodnie in Wroclaw, clinical research in Digestive System Diseases focuses on ulcerative colitis, with studies designed to assess whether new treatment options can provide similar or better control of symptoms while maintaining safety and tolerability.
- Evaluating a potential new therapy for moderately to severely active ulcerative colitis
- Comparing treatment effectiveness against an established licensed option
- Supporting better care for inflammatory bowel disease through safety and response data
This area reflects a practical effort to improve treatment choices for people living with chronic intestinal inflammation.
Neoplasms
The site is also involved in Neoplasms research, mainly centered on prostate cancer, with trials that aim to gather longer-term safety information and understand how ongoing treatment may continue to benefit patients after earlier study participation.
- Studying treatment safety in men with prostate cancer
- Following patients who previously took part in an enzalutamide study
- Generating evidence to support continued cancer care decisions
This work helps expand knowledge about sustained treatment use and patient outcomes in oncology.
Mental Disorders
In Mental Disorders research, Penta Hospitals Przychodnie is contributing to studies in mild to moderate Alzheimer’s disease, with a focus on whether investigational treatment approaches can improve thinking skills and day-to-day functioning.
- Assessing cognitive improvement in Alzheimer’s disease
- Measuring changes in global functioning and impairment
- Exploring new options for people with early-stage dementia-related symptoms
These trials aim to better understand how emerging therapies may support both cognition and overall quality of life in Alzheimer’s disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Penta Hospitals Przychodnie
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE) | Polpharma Biologics S.A. | Phase III | Not Recruiting | Nov 2023 | Apr 2026 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abiraterone | 1 | Unknown | 2016-11-29 | 2016-11-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.